Alexandra McMellen
Overview
Explore the profile of Alexandra McMellen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin S, Nguyen L, McMellen A, Leibowitz M, Davidson N, Spinosa D, et al.
Mol Diagn Ther
. 2024 Nov;
29(2):145-151.
PMID: 39557776
To better understand ovarian cancer lethality and treatment resistance, sophisticated computational approaches are required that address the complexity of the tumor microenvironment, genomic heterogeneity, and tumor evolution. The ovarian cancer...
2.
Bitler B, Bailey C, Yamamoto T, McMellen A, Kim H, Watson Z
Mol Carcinog
. 2023 Jul;
62(11):1717-1730.
PMID: 37493106
PARP inhibitors (PARPi) kill cancer cells by stalling DNA replication and preventing DNA repair, resulting in a critical accumulation of DNA damage. Resistance to PARPi is a growing clinical problem...
3.
Klosowski M, Haines L, Alfino L, McMellen A, Leibowitz M, Regan D
Front Oncol
. 2023 Apr;
13:1130215.
PMID: 37035209
Fueled by support from the National Cancer Institute's "Cancer Moonshot" program, the past few years have witnessed a renewed interest in the canine spontaneous cancer model as an invaluable resource...
4.
McMellen A, Yamamoto T, Qamar L, Sanders B, Nguyen L, Ortiz Chavez D, et al.
Mol Cancer Res
. 2022 Sep;
21(1):3-13.
PMID: 36149636
Implications: This study highlights that a novel p38-ATF6-mediated AP-1 signaling axis contributes to PARPi resistance and provides a clinical rationale for combining PARPi and AP-1 signaling inhibitors.
5.
Sanders B, Yamamoto T, McMellen A, Woodruff E, Berning A, Post M, et al.
Mol Cancer Ther
. 2022 May;
21(8):1285-1295.
PMID: 35587258
Identifying novel, durable treatments for high-grade serous ovarian cancer (HGSOC) is paramount to extend both progression-free survival (PFS) and overall survival (OS) in patients afflicted with this disease. Dual-specificity phosphatase...
6.
McMellen A, Woodruff E, Corr B, Bitler B, Moroney M
Int J Mol Sci
. 2020 Jun;
21(12).
PMID: 32560059
Gynecologic malignancies, including ovarian cancer, endometrial cancer, and cervical cancer, affect hundreds of thousands of women worldwide every year. Wnt signaling, specifically Wnt/β-catenin signaling, has been found to play an...
7.
Sawyer B, Qamar L, Yamamoto T, McMellen A, Watson Z, Richer J, et al.
Mol Cancer Res
. 2020 Mar;
18(7):1088-1098.
PMID: 32198139
Epithelial-derived high-grade serous ovarian cancer (HGSOC) is the deadliest gynecologic malignancy. Roughly 80% of patients are diagnosed with late-stage disease, which is defined by wide-spread cancer dissemination throughout the pelvic...
8.
Watson Z, Yamamoto T, McMellen A, Kim H, Hughes C, Wheeler L, et al.
Clin Epigenetics
. 2019 Nov;
11(1):165.
PMID: 31775874
Background: Euchromatic histone-lysine-N-methyltransferases 1 and 2 (EHMT1/2, aka GLP/G9A) catalyze dimethylation of histone H3 lysine 9 (H3K9me2) and have roles in epigenetic silencing of gene expression. EHMT1/2 also have direct...
9.
Yamamoto T, McMellen A, Watson Z, Aguilera J, Ferguson R, Nurmemmedov E, et al.
Mol Carcinog
. 2019 Jun;
58(10):1770-1782.
PMID: 31219654
Epithelial ovarian cancer (EOC) has one of the highest death to incidence ratios among all cancers. High grade serous ovarian carcinoma (HGSOC) is the most common and deadliest EOC histotype...